Gilead

Sompo Japan Nipponkoa Asset Management CO. LTD. Sells 4,970 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 5/24/2020

Sompo Japan Nipponkoa Asset Management CO. LTD. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,520 shares of the biopharmaceutical company’s stock after selling 4,970 shares during the quarter. Sompo Japan Nipponkoa Asset Management CO. LTD.’s holdings in Gilead Sciences were worth $2,655,000 …

Mutual of America Capital Management LLC Buys 867 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - TheOlympiaReport | 5/24/2020

Mutual of America Capital Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,432 shares of the biopharmaceutical company’s stock after buying an additional 867 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Gilead Sciences were worth $21,115,000 …

Follow Gilead:    

Blair William & Co. IL Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD) - Stock Observer | 5/24/2020

Blair William & Co. IL trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 804,257 shares of the biopharmaceutical company’s stock after selling 128,459 shares during the period. Blair William & Co. IL owned about 0.06% of Gilead Sciences worth $60,126,000 at the end of the most recent reporting period …

Cigna Investments Inc. New Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - Stock Observer | 5/24/2020

Cigna Investments Inc. New raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 35,777 shares of the biopharmaceutical company’s stock after acquiring an additional 2,150 shares during the quarter. Cigna Investments Inc. New’s holdings in Gilead Sciences were worth $2,675,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have …

Sequoia Financial Advisors LLC Has $2.24 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - Stock Observer | 5/24/2020

Sequoia Financial Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,947 shares of the biopharmaceutical company’s stock after buying an additional 1,198 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Gilead Sciences were worth $2,239,000 as of its most recent SEC filing. A …

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund | 5/24/2020

Fjarde AP Fonden Fourth Swedish National Pension Fund Posted by Carolyn Dwyer on May 23rd, 2020 Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 351,328 shares of the biopharmaceutical company’s stock after selling 11,000 shares during the quarter. Fjarde AP …

Cigna Investments Inc. New Buys 2,150 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 5/24/2020

Cigna Investments Inc. New lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,777 shares of the biopharmaceutical company’s stock after acquiring an additional 2,150 shares during the quarter. Cigna Investments Inc. New’s holdings in Gilead Sciences were worth $2,675,000 as of its most …

Sequoia Financial Advisors LLC Buys 1,198 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 5/24/2020

Sequoia Financial Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,947 shares of the biopharmaceutical company’s stock after purchasing an additional 1,198 shares during the period. Sequoia Financial Advisors LLC’s holdings in Gilead Sciences were worth $2,239,000 as of its most recent filing with the SEC. Several …

Gilead Sciences (NASDAQ:GILD) Downgraded by BidaskClub | 5/24/2020

Gilead Sciences (NASDAQ:GILD) Downgraded by BidaskClub Posted by Devon Dixon on May 23rd, 2020 Tweet BidaskClub lowered shares of Gilead Sciences (NASDAQ:GILD) from a hold rating to a sell rating in a research report released on Wednesday morning, BidAskClub reports. A number of other equities research analysts also recently weighed in on GILD. Jefferies Financial Group reissued a buy rating and set a $89.00 target price on shares …

Diffuse Large B-Cell Lymphoma Market 2017-2025 : F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Gilead Sciences, Inc. | 5/23/2020

RSS Diffuse Large B-Cell Lymphoma Market 2017-2025 : F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Gilead Sciences, Inc. This research report offers a detailed evaluation of the global diffuse large B-Cell lymphoma market on the basis of its current and historical performance. San Francisco, CA – ( SBWIRE ) – 05/22/2020 – Diffuse Large B-Cell Lymphoma Market: Overview With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the …

How some states are allocating their share of COVID-19 drug | Becker’s Hospital Review | 5/23/2020

… may be drastically different, according to The Wall Street Journal . Remdesivir is the first drug to have shown efficacy in treating COVID-19, moderately speeding up recovery among patients, according to a federal study. Gilead Sciences, the maker of the drug, is donating 940,000 does of it to the federal government over the next six weeks, which will be distributed among hospitals by state officials. But there is little clear …

Peer-reviewed data shows Gilead’s drug effective against COVID-19: NIH | 5/23/2020

Reuters) - The National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine from a trial testing Gilead Sciences Inc’s remdesivir showed the drug was superior to the standard of care for COVID-19. Last month, the NIH announced early data from the study, which began in February with 1,063 participants in 10 countries.(https://bit.ly/2Tvd6I1) (Reporting by Manojna Maddipatla in …

Front Row Advisors LLC Purchases 595 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 5/23/2020

Front Row Advisors LLC Purchases 595 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Posted by Matthew Tipps on May 22nd, 2020 Front Row Advisors LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,266 shares of the biopharmaceutical company’s stock after buying an additional 595 …

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Gamble Jones Investment Counsel | 5/23/2020

Gamble Jones Investment Counsel trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,855 shares of the biopharmaceutical company’s stock after selling 345 shares during the quarter. Gamble Jones Investment Counsel’s holdings in Gilead Sciences were worth $512,000 at the end of the most recent reporting period. Several …

Royal Fund Management LLC Invests $207,000 in Gilead Sciences, Inc. (NASDAQ:GILD) | 5/23/2020

Royal Fund Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,779 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Several other institutional investors have also recently bought and sold shares of the company. Front Row Advisors LLC boosted its holdings in shares of …

Peer-reviewed data shows Gilead’s drug helps COVID-19 recovery time | Physicians Weekly | 5/23/2020

Peer-reviewed data shows Gilead’s drug helps COVID-19 recovery time May 22, 2020 By Deena Beasley (Reuters) – The U.S. National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc’s GILD.O remdesivir is effective at helping COVID-19 patients recover. The trial, for which final results are still trickling in, showed that recovery time for patients …

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) | 5/23/2020

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 258,070 shares of the biopharmaceutical company’s stock after buying an additional 4,951 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Gilead Sciences were …

NIH Trial: Gilead’s Drug Works Best in COVID Patients on Oxygen | U.S. News & World Report | 5/23/2020

… of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo Reuters By Deena Beasley (Reuters) - The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation. The peer-reviewed data was published in the New England …

Banco Santander S.A. Purchases 1,228,709 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 5/23/2020

Banco Santander S.A. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7,911.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,244,240 shares of the biopharmaceutical company’s stock after purchasing an additional 1,228,709 shares during the quarter. Gilead Sciences makes up 1.1% of Banco Santander S.A.’s portfolio, making the stock its 13th largest …

NIH trial: Gilead’s drug works best in COVID patients on oxygen | 5/23/2020

The U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation. from Reuters: Health News https://uk.reuters.com/article/us-health-coronavirus-gilead-sciences/nih-trial-gileads-drug-works-best-in-covid-patients-on-oxygen-idUKKBN22Y30B?feedType=RSS&feedName=healthNews …

Covid-19 study details benefits of treatment with remdesivir, and also its limitations | STAT | 5/23/2020

Health Covid-19 study details benefits of treatment with remdesivir, and also its limitations By Matthew Herper @matthewherper May 22, 2020 A vial of the Gilead drug remdesivir. Gilead Sciences via AP R emdesivir, the only drug cleared to treat Covid-19, sped the recovery time of patients with the disease, but its benefit appeared much more limited in patients who needed mechanical ventilation as part of their treatment, according …

4,501 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Toroso Investments LLC | 5/23/2020

Toroso Investments LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,501 shares of the biopharmaceutical company’s stock, valued at approximately $336,000. A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Norges Bank acquired …

Gamble Jones Investment Counsel Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - Stock Observer | 5/23/2020

Gamble Jones Investment Counsel lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,855 shares of the biopharmaceutical company’s stock after selling 345 shares during the period. Gamble Jones Investment Counsel’s holdings in Gilead Sciences were worth $512,000 as of its most recent …

Bay Area: Gilead revealed patients’ HIV concerns, lawsuit claims | The Mercury News | 5/23/2020

Foster City pharmaceutical firm Gilead Sciences, lately in the news for its possible coronavirus-treatment drug remdesivir, sent patients taking HIV drugs letters in envelopes that revealed they were had issues related to the virus, a new lawsuit seeking class action claims. Two men, from Alabama and Indiana, said in the suit that they were among hundreds of patients taking Gilead’s HIV treatment and prevention drugs and enrolled in a …

Peer-reviewed data shows Gilead’s drug effective against COVID-19 | 5/23/2020

FILE PHOTO: A vial of redesivir By Deena Beasley (Reuters) - The U.S. National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc’s remdesivir is effective at helping COVID-19 patients recover. The trial, for which final results are still trickling in, showed that recovery time for patients given remdesivir was shortened by four days, or 31 …

Biotech

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… ofatumumab might also come late, ODDO BHF analysts noted recently. Register for the On-Demand Webinar Rollouts from small-cap biotechs with little to no marketing experience are likely most vulnerable, however. So are new … the market. Potential inspection, approval and launch delays will place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED …

COVID-19

Swiss Government Expands Powers to Force Firms to Make Supplies to Fight COVID-19 | U.S. News & World Report | 4/3/2020

Swiss Government Expands Powers to Force Firms to Make Supplies to Fight COVID-19 April 3, 2020 More ZURICH (Reuters) - The Swiss government on Friday boosted its powers to order companies to raise production of … which has been donated by Novartis, Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are now being studied for potential use against coronavirus. Swissmedic also gets new powers to …

Food and Drug Administration

Amgen, Adaptive to develop Covid-19 drugs using antibodies from recovered patients - MedCity News | 4/2/2020

Gilead Sciences is developing an antiviral, remdesivir, while Regeneron Pharmaceuticals and Sanofi are developing Kevzara (sarilumab). Moderna’s Phase I trial of the vaccine mRNA-1273 dosed its first patient last month, and companies like Vir Biotechnology are developing therapies of their own. Amgen and Adaptive’s effort could benefit from a new program that the Food and Drug Administration announced Tuesday, the Coronavirus Treatment Acceleration Program, or CTAP, which is designed …

National Cancer Institute

Gilead’s Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma | FierceBiotech | 4/2/2020

Gilead Sciences’ Kite Pharma is working on new CAR-T therapies for these patients—and it’s enlisted Teneobio’s antibody technology to do so. Under the deal , Kite is licensing a suite of antibodies from Teneobio that target BCMA, including one currently in a phase 1 study for multiple myeloma at the National Cancer Institute. The pair will also use Teneobio’s Human Heavy-Chain Antibodies (UniAb) platform to discover antibodies for …

Clinical Research

EuroBiotech Report—Lilly-Sitryx, Genfit and COVID-19, Gilead tests remdesivir in U.K. and more | FierceBiotech | 4/2/2020

Gilead began to test its antiviral remdesivir in the U.K. The NIHR Clinical Research Network, a major U.K. biomedical body, shut down in response to COVID-19 And more. — Nick Taylor 1. Lilly pays Sitryx $50M upfront for preclinical autoimmune assets Eli Lilly has paid Sitryx $50 million (€46 million) upfront for global rights to up to four autoimmune drugs. The deal sees Lilly commit to up to $820 million …

Regenerative Medicine

Vaccine for COVID-19 Health Crises “Possible” by Summer After FDA Fast-Tracks Clinical Trials | PR Newswire | 4/1/2020

… a vaccine is still under development. Reuters reported that the President, speaking at a news conference, pointed to efforts on Gilead Sciences Inc’s experimental antiviral drug Remdesivir and the generic antimalarial drug hydroxychloroquine, saying he … well-positioned to deliver on the promise of our innovative regenerative medicine technology, and to helping advance the boundaries of medicine in areas where there is a substantial unmet medical need. Maia brings tremendous experience …

National Institutes of Health

Chicago-area hospitals begin COVID-19 drug trial | Modern Healthcare | 4/1/2020

… patients. Cook County Health is also treating hospitalized patients with remdesivir in two clinical trials sponsored by the drug manufacturer, Gilead Sciences. Cook County is treating patients with moderate COVID-19 in one study and … 440 patients, which is sponsored by a division of the National Institutes of Health. The study is an adaptive, randomized, double-blind, placebo-controlled trial, according to the NIH …

NIH

Chicago-area hospitals begin COVID-19 drug trial | Modern Healthcare | 4/1/2020

… patients. Cook County Health is also treating hospitalized patients with remdesivir in two clinical trials sponsored by the drug manufacturer, Gilead Sciences. Cook County is treating patients with moderate COVID-19 in one study and … adaptive, randomized, double-blind, placebo-controlled trial, according to the NIH

National Institute of Allergy and Infectious Diseases

Report: Trump sets sights on another unproven Covid-19 drug, this time from Fujifilm - MedCity News | 4/1/2020

… antiviral effect against viruses other than influenza because its mechanism of action inhibits viral gene replication inside infected cells. A National Institute of Allergy and Infectious Diseases spokesperson said the drug is one of multiple … Other drugs currently in clinical development for Covid-19 include Gilead Sciences’ remdesivir, Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab). Gilead is expected to have data for remdesivir this month. Photo: FDA (free of all copyright …

Digital Health

J&J’s coronavirus vaccine could hit the market by 2021 | Fortune | 3/31/2020

… change. Read on for the day’s news—and see you again on Thursday. Sy Mukherjee [email protected] @the_sy_guy DIGITAL HEALTH \n An Australian company is trying to make computer chips from human neurons … consumption,” my colleague Jeremy Kahn reports . ( Fortune ) \n INDICATIONS \n Gilead shakes up its coronavirus antiviral strategy. The saga of Gilead’s coronavirus antiviral continues. At first, the company’s drug had so much demand under a …

Big Pharma

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

Big Pharma include AbbVie’s Skyrizi and Roche’s Xofluza, while smaller pharma brands still vying for the top title include Alnylam’s Onpattro and Evolus’ Jeuveau. Recapping the last round’s action in the Infectious Diseases/Primary Care division, Takeda’s Motegrity trounced Gilead’s Biktarvy and Amgen’s Evenity took out AbbVie’s Rinvoq. The integrity-like name from Takeda held strong for voters, although other associations, like “scooter-share company,” also won Motegrity votes. In …

CDC

Under intense criticism, Gilead forsakes monopoly status for its experimental Covid-19 drug | 3/27/2020

… Bottles of remdesivir in a hospital for COVID-19 patients in Wuhan. FeatureChina via AP I n an unexpected move, Gilead Sciences ( GILD ) has asked the Food and Drug Administration to rescind orphan drug designation … that Covid-19 was spreading in the U.S. and the CDC was warning it could be a pandemic.” (You can look here to get an idea). The advocacy group also released a paper suggesting that …

Coronavirus

Coronavirus treatment: Gilead’s FDA request for its COVID-19 drug remdesivir | Fortune | 3/26/2020

Happy Wednesday, readers. Remdesivir, the experimental COVID-19 treatment from Gilead , has been one of the drugs thought to have the most potential to treat the novel coronavirus. It’s already been deployed in the U.S. and multiple other countries as this pandemic spreads. During, say, any other time in the history of the biotech industry, that’s an advantage a corporation would likely hold onto. Clearly, these aren’t normal times. More …

Telehealth

WHO Officials Indicating at Least 20 Vaccines in Development in Global Race for a Cure | PR Newswire | 3/25/2020

… losartan as a possible treatment for the disease. Active healthcare stocks in news today include : BioSig Technologies, Inc. (NASDAQ: BSGM ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), IMAC Holdings, Inc. (NASDAQ: IMAC … surgery or opioids, recently announced it has implemented a new telehealth option to allow active care patients direct and consistent communications with IMAC medical professionals even while observing “shelter in place” status. The telehealth option …

Medical Research

Gilead hits brakes on compassionate use program for Covid-19 drug, citing surge in requests - MedCity News | 3/23/2020

… for its clinical trials to access the drug as it has seen a surge in demand. Foster City, California-based Gilead Sciences issued a statement that it received a flood of compassionate use requests for … expanded-access program for remdesivir, sponsored by the U.S. Army Medical Research and Development Command. That’s in addition to two randomized Phase III clinical trials that Gilead is running, as well as a Phase II …

Mental Health

Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials | Business Wire | 3/20/2020

… clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus. Feinstein Institutes researchers are teaming up with Gilead Sciences , Regeneron Pharmaceuticals and Sanofi to identify effective treatments for patients currently hospitalized in … molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For …

CAR-T

Allogene chair, former Kite Pharma CEO Belldegrun reveals COVID-19 diagnosis | FierceBiotech | 3/16/2020

A “minimal dry cough and transient low-grade fever” led to biotech veteran Arie Belldegrun being diagnosed with COVID-19 as the U.S. and the world issue tighter crackdowns to keep this new coronavirus under control. Belldegrun, who helmed CAR-T biotech star Kite Pharma before its $12.9 billion sale to Gilead Sciences a few years back, now chairs next-gen cell therapy biotech Allogene . He took to Twitter over …

Population Health

Fibrosis linked with mortality, liver-related morbidity risk in patients with NAFLD | 2/6/2020

… regardless of confounding factors and in patients with NASH, according to study results. Rod S. Taylor, MSc, PHD, chair of population health research at the University of Glasgow, and colleagues wrote that it is widely … NASH.”– by Alex Young Disclosure: Taylor reports receiving funding from Gilead. Please see the full guidelines for all other authors’ relevant financial disclosures. Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related …

American College of Rheumatology

Start with Anti-TNF in RA? Not So Fast | 1/31/2020

… was no significant difference (94% vs 89%, OR 1.88, 95% CI 0.43-8.18). Similarly, 20% improvements on the criteria of the American College of Rheumatology were seen in 75% of the etanercept group compared with 55 … Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Celgene, Cyxone, Daichii, Eisai, Galapagos, Gilead, GlaxoSmithKline, Janssen, Regeneron, Roche, and Takeda. 1969-12-31T19:00:00-0500 …

Clinical Collaboration

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts | Globe Newswire | 1/13/2020

Gilead company (Kite), recently announced a clinical collaboration evaluating the investigational combination of Yescarta ® (axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large B-cell lymphoma. The objective of the study is to determine the effect of mavrilimumab on the safety of Yescarta. Preclinical evidence shows the potential for interruption of granulocyte macrophage colony stimulating factor (GM-CSF) signaling to disrupt chimeric antigen receptor T (CAR T) cell-mediated inflammation …

Medicaid

Viewpoints: Lessons On Why Opposition To Medicaid Expansion Lost Ground In Even Red States; In The U.S., Expensive Breakthrough Therapies For Certain Cancers Have Vastly Improved Life | Kaiser Health News | 1/10/2020

… in on health care reform issues and other health topics. The Washington Post: Have Republicans Lost The Argument Over The Medicaid Expansion? In all, 37 states have now expanded Medicaid — many of them red — while … biopharma companies, like Bristol-Myers Squibb/Celgene acquiring Juno or Gilead acquiring Kite. (Vijay Pande, 1/10) The Washington Post: In D.C., Getting Rid Of Tents And Benches Used By Homeless Won’t Make Homelessness Go Away …

Department of Health and Human Services

Oncologist Stephen Hahn Confirmed As FDA Commissioner | MedCity News | 12/12/2019

… month to succeed former Commissioner Scott Gottlieb, who stepped down in March. National Cancer Institute Director Dr. Ned Sharpless and Department of Health and Human Services official Dr. Brett Giroir had been heading the FDA … the latter of which it is developing with bluebird bio . Gilead Sciences said Wednesday that it had filed for approval of KTE-X19 in mantle cell lymphoma as well. And bluebird plans to initiate a …

Medicare

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… meanwhile, is out of step with the Democratic Party and the general electorate with her call for a single-payer “Medicare for All” system that would supplant the private insurance market altogether. (12/3) The Hill … or PrEP, that were promised in May by the drugmaker Gilead Sciences. (McNeil, 12/3) The Associated Press: Health Program Offers Free HIV Prevention Drug To Uninsured Expanding access to what’s called PrEP — for pre-exposure …

University of Utah

Robert Gehrke: These Utahns are working to make sure the terror of the AIDS epidemic remains in the past - The Salt Lake Tribune | 12/4/2019

… started treatment at San Francisco General Hospital, but eventually ended up getting treated by Kristen Riess, a doctor at the University of Utah and a pioneer in the field of HIV treatment. Lawrence was one … of the daily pills costs about $7 to make, but Gilead Sciences, which has patented the drug, charges about $1,800, putting it out of reach for the uninsured. (The federal government is suing Gilead, alleging …

Kaiser Family Foundation

HHS Hands Out Free HIV Prevention Drugs. Do You Qualify? | Kaiser Health News | 12/4/2019

… trump-administration-secures-historic-donation-of-billions-of-dollars-in-hiv-prevention-drugs.html” a donation /a from the drugs’ manufacturer, Gilead Sciences. That would cover the drugs for up to 200,000 uninsured individuals each year … independent program of the a href=”http://www.kff.org/” Henry J. Kaiser Family Foundation /a which is not affiliated with Kaiser Permanente. /p …

Pfizer

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice | BMJ | 4/3/2020

Pfizer and Janssen; and is a shareholder in BiomeBank. JMA has received speaker fees, research funding, educational support or honoraria for advisory board participation from Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, Celegene, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Shire, Takeda, Vifor, Royal Adelaide Research Fund and The Hospital Research Fund. JB has received speaker fees, research funding, educational support or honoraria for advisory board participation from …

Celgene

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED: Bristol Myers nabs long-sought FDA nod for Celgene’s MS drug ozanimod, but pandemic delays launch As for Biogen, the Big Biotech is grappling with the coronavirus from within as several members of senior management have been infected. Therefore, regulatory filing or review of its …

AbbVie

Swiss Government Expands Powers to Force Firms to Make Supplies to Fight COVID-19 | U.S. News & World Report | 4/3/2020

… Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are now being studied for potential use against coronavirus. Swissmedic also gets new powers to approve deviations from some legal requirements for drugs under review, the government said. (Reporting by John Miller; Editing by Michael Shields) Copyright 2020 Thomson Reuters …

Biogen

COVID-19 is bad news for new drug launches. Which will suffer most? | FiercePharma | 4/3/2020

… Biogen’s tried-and-true oral Spinraza on the market. Potential inspection, approval and launch delays will place Gilead Sciences and Galapagos’ JAK inhibitor filgotinib farther behind AbbVie’s Rinvoq in rheumatoid arthritis, RBC Capital analyst Brian Abrahams noted in a recent report. RELATED: Bristol Myers nabs long-sought FDA nod for Celgene’s MS drug ozanimod, but pandemic delays launch As for Biogen, the Big Biotech is grappling with the coronavirus from …

Novartis

Swiss Government Expands Powers to Force Firms to Make Supplies to Fight COVID-19 | U.S. News & World Report | 4/3/2020

… Novartis, Abbvie’s HIV drug Kaletra, Gilead Science’s experimental remdesivir and Roche’s Actemra, all of which are now being studied for potential use against coronavirus. Swissmedic also gets new powers to approve deviations from some legal requirements for drugs under review, the government said. (Reporting by John Miller; Editing by Michael Shields) Copyright 2020 Thomson Reuters …

Allergan

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice | BMJ | 4/3/2020

… Allergan, Anatara, AstraZeneca, Bayer, Celegene, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Shire, Takeda, Vifor, Royal Adelaide Research Fund and The Hospital Research Fund. JB has received speaker fees, research funding, educational support or honoraria for advisory board participation from Janssen, Takeda, AbbVie, Celgene, Ferring, Pfizer, Anatara, Microba, Shire and Progenity. SC has received speaker fees, research funding, educational support or honoraria for advisory board participation from …

GSK

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice | BMJ | 4/3/2020

… Therapeutics and received speaker fees from Ferring, Janssen. TJB has interest in Redhill Biopharma, Salix and Finch Therapeutics, ResMed and GSK; has interest in the Centre for Digestive Diseases, where faecal microbiota transplantation is a … participation from Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, Celegene, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Shire, Takeda, Vifor, Royal Adelaide Research Fund and The Hospital Research Fund. JB has received speaker …

Amgen

Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN) - April 3, 2020 - Zacks.com | 4/3/2020

Gilead Sciences ( GILD - Free Report ) and other giants such as Amgen ( AMGN - Free Report ) and Johnson & Johnson ( JNJ - Free Report ) have also joined the fight against the global pandemic. More broadly, Regeneron is a biotech firm that has seven FDA-approved treatments and “numerous product candidates in development.” The company’s current offerings and pipeline aim to help people with everything from allergic and inflammatory diseases to cancer, infectious diseases, and …

Johnson & Johnson

Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN) - April 3, 2020 - Zacks.com | 4/3/2020

Gilead Sciences ( GILD - Free Report ) and other giants such as Amgen ( AMGN - Free Report ) and Johnson & Johnson ( JNJ - Free Report ) have also joined the fight against the global pandemic. More broadly, Regeneron is a biotech firm that has seven FDA-approved treatments and “numerous product candidates in development.” The company’s current offerings and pipeline aim to help people with everything from allergic and inflammatory diseases to cancer, infectious diseases, and …

AstraZeneca

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice | BMJ | 4/3/2020

… AstraZeneca, Bayer, Celegene, Ferring, Gilead, Hospira, Immuninc, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Shire, Takeda, Vifor, Royal Adelaide Research Fund and The Hospital Research Fund. JB has received speaker fees, research funding, educational support or honoraria for advisory board participation from Janssen, Takeda, AbbVie, Celgene, Ferring, Pfizer, Anatara, Microba, Shire and Progenity. SC has received speaker fees, research funding, educational support or honoraria for advisory board participation from AbbVie, Aspen …

Eli Lilly

EuroBiotech Report—Lilly-Sitryx, Genfit and COVID-19, Gilead tests remdesivir in U.K. and more | FierceBiotech | 4/2/2020

… Eli Lilly. Sitryx granted Lilly rights to up to four preclinical autoimmune assets in return for $50 million upfront and many times as much in milestones. Elsewhere, COVID-19 dominated the headlines. Genfit told investors that it does not expect the COVID-19 pandemic to “significantly delay” the unblinding of its phase 3 nonalcoholic steatohepatitis data. Gilead began to test its antiviral remdesivir in the U.K. The NIHR Clinical Research …

Amazon Health

Can Buffett-Style Investing Succeed Today? Stocks & ETFs to Consider - April 2, 2020 - Zacks.com | 4/2/2020

Amazon ( AMZN - Free Report ) is the top holding in the portfolio. The largest online retailer has seen a surge in business since the start of the crisis. It is also the largest player in cloud computing, which has seen an exponential increase in usage by companies as their employees are working from home now. Another top holding—ServiceNow ( NOW - Free Report ) –provides enterprise cloud computing solutions. Biotech giant Gilead ( GILD …

Bristol-Myers Squibb

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first approved CAR-T cell … tisagenlecleucel), for pediatric acute lymphoblastic leukemia and adult DLBCL; and Gilead Sciences’ Yescarta (axicabtagene ciloleucel), for DLBCL alone. If approved, ide-cel would be the first CAR-T for an indication outside of leukemia or …

Bristol-Myers

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

Drugmaker Bristol-Myers Squibb and a biotech company with which it has partnered have sent their application to the Food and Drug Administration seeking approval for what could become the first approved CAR-T cell … tisagenlecleucel), for pediatric acute lymphoblastic leukemia and adult DLBCL; and Gilead Sciences’ Yescarta (axicabtagene ciloleucel), for DLBCL alone. If approved, ide-cel would be the first CAR-T for an indication outside of leukemia or …

GlaxoSmithKline

BMS, bluebird file for approval of CAR-T cell therapy for multiple myeloma - MedCity News | 4/1/2020

… Two CAR-T cell therapies are currently approved: Novartis’ Kymriah (tisagenlecleucel), for pediatric acute lymphoblastic leukemia and adult DLBCL; and Gilead Sciences’ Yescarta (axicabtagene ciloleucel), for DLBCL alone. If approved, ide-cel would be the … cell engager, while Amgen has AMG 420, a bispecific antibody. GlaxoSmithKline , meanwhile, expects that the FDA will rule in the first half of this year on belantamab mafodotin, an antibody-drug conjugate that could become …

Illumina

10 Best Stocks in Nasdaq for March; Buy or Sell? - TheStreet | 4/1/2020

The best stocks in the Nasdaq for March include Amazon, Gilead Sciences and Netflix. See the best stocks in the Nasdaq for March 2020. Author: Danny Peterson Updated: Apr 1, 2020 9:37 AM EDT Original … as a Buy with a rating score of B. 8. Illumina ILMN +2.8% Closing Price $273.12 TheStreet Quant Ratings rates Illumina as a Buy with a rating score of B-. 9. Biogen BIIB +2.59% Closing …

Abbott Laboratories

Wall Street, welcoming health measures, continues its rebound | Yahoo News | 3/31/2020

Abbott Laboratories (+ 6.4%) which is working on a coronavirus screening test in five minutes and Johnson & Johnson (+8.01 %) who plans to launch a clinical trial for a vaccine in September. Oil at its lowest since 2002 Other laboratories working on treatments such as Regeneron (+ 5.22%), Biogen (+ 6.53%) or Gilead (+ 4.23%) have also progressed. The sub-index representing the health sector in the S&P 500 jumped 4.7% on Monday. Boeing …

Merck

#FierceMadness: Big brands and underdogs—Onpattro and Jeuveau included—make the Sweet 16 cut | FiercePharma | 3/30/2020

… Gilead’s Biktarvy and Amgen’s Evenity took out AbbVie’s Rinvoq. The integrity-like name from Takeda held strong for voters, although other associations, like “scooter-share company,” also won Motegrity votes. In the same division, Roche’s Xofluza topped Merck’s Ervebo, with voters favoring the flu treatment with comments that indicated we can’t escape COVID-19 even in FierceMadness-land. One commenter spoke for many, writing, “In the current moment, anything with …

Inovio

These companies are racing to roll out COVID-19 treatments - CNN | 3/30/2020

… on the news Monday. Many other companies are also working on vaccines, including small biotechs Moderna ( MRNA ) , Novavax ( NVAX ) and Inovio ( INO ) as well as Big Pharma firm Pfizer ( PFE ) , which is partnering with Germany’s … gotten the most attention – is remdesivir, a drug made by Gilead Sciences ( GILD ) that was originally used for Ebola and other highly contagious diseases. Drug companies race to test coronavirus vaccines Officials at the World …

Qiagen

Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study | BMJ | 3/26/2020

… Gilead, outside the submitted work. SB reports grants, personal fees and other from Gilead; grants, personal fees and other from AbbVie; all outside the submitted work. RF reports personal fees from Gilead, outside the submitted work. KT reports grants from GenMark, grants from Cepheid, grants from Qiagen, other from SpeedX, all outside the submitted work. PCH reports personal fees from Gilead, personal fees from AbbVie, personal fees from BMS, personal …

HealthDay

Health Highlights: March 26, 2020 | U.S. News & World Report | 3/26/2020

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Gilead Backs Down on Special Designation for Possible Coronavirus Drug Following severe criticism, Gilead Sciences is backing off special designation of its antiviral drug remdesivir – which shows promise against the coronavirus – that would have allowed the company to block competition and increase its profits for the drug. Gilead asked the U.S. Food and …

Genentech

S.F. biotech races potential COVID-19 drug toward clinical trial | The Business Journals | 3/25/2020

Gilead Sciences Inc. (NASDAQ: GILD) is in five clinical trials globally, including two by the company, for COVID. Genentech Inc. of South San Francisco also is starting a COVID clinical trial for its already-approved rheumatoid arthritis drug Actemra. What’s more, the Food and Drug Administration said Tuesday that it will allow so-called convalescent plasma — derived from the antibody-rich blood of patients who have recovered from the disease …

Teva Pharmaceutical

Coronavirus Drugs Already in the Pipeline | Yahoo News | 3/25/2020

… chloroquine family) or flu drugs (favipiravir) The antimalarials are in short supply, but production is ramping up. Mylan ( MYL ) and Teva Pharmaceuticals ( TEVA ) plan to jump-start production of hydroxychloroquine, which is also approved for … something” approach, to the point that demand led its manufacturer, Gilead ( GILD ), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in …

Teva Pharmaceutical

Coronavirus Drugs Already in the Pipeline | Yahoo News | 3/25/2020

… chloroquine family) or flu drugs (favipiravir) The antimalarials are in short supply, but production is ramping up. Mylan ( MYL ) and Teva Pharmaceuticals ( TEVA ) plan to jump-start production of hydroxychloroquine, which is also approved for … something” approach, to the point that demand led its manufacturer, Gilead ( GILD ), to limit its used to clinical trials. Six large studies are ongoing. The first should report results on April 3, the second in …

Eli Lilly & Company

Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure - March 24, 2020 - Zacks.com | 3/24/2020

Eli Lilly & Company ( LLY - Free Report ) announced that it is halting enrollment in most ongoing studies and will delay new study starts in order to allow doctors and healthcare facilities to focus on efforts to … making new antibodies, drugs and vaccines to combat the disease. Gilead’s ( GILD - Free Report ) investigational antiviral candidate, remdesivir, is being evaluated in phase III studies to treat COVID-19. Regeneron ( REGN - Free Report ) has identified …

Morgan Stanley

U.S. Stock Funds Say Goodbye Bull Market, Hello Volatility at Quarter-End | Morningstar | 3/31/2020

… S&P 500 posted gains from the market’s Feb. 20 top through March 27: biotech firms Regeneron Pharmaceuticals ( REGN ) and Gilead Sciences ( GILD ) , Kroger ( KR ) , and Clorox ( CLX ) . Energy stocks fell the hardest as the … this quarter; even the best-performing equity funds lost money. Morgan Stanley Institutional Growth ( MSEQX ) , which has a Morningstar Analyst Rating of Bronze, held up the best of any rated equity fund with a 4.1 …

Goldman Sachs

Gilead Sciences Expects Coronavirus Drug Data in Coming Weeks, Expands Access | Yahoo News | 3/29/2020

Gilead Sciences Expects Coronavirus Drug Data in Coming Weeks, Expands Access Gilead Sciences Inc. (GILD) said it is expecting to have initial remdesivir drug data in coming weeks. The experimental drug is currently being evaluated … Pershing No Longer Has Hedges, But Cash For Stock Investments Goldman Sachs Picks 2 Stocks to Buy (and 1 to Sell) 2 Biotech Giants in the Hunt for New Coronavirus Drugs Hedge Fund Billionaire Ackman …

Citigroup

Stocks making the biggest moves midday: DXC Technology, Apache & more | CNBC | 3/11/2020

… 350. The analyst said 5G iPhones may be delayed as Apple’s supply chains remain under pressure amid the coronavirus outbreak. Citigroup , Wells Fargo — Bank stocks fell sharply in Wednesday morning’s trading, with several major names … than 14%, while Royal Caribbean and Carnival dropped 9% each. Gilead — The Foster City, California-based biotech company represented one of just a handful of S&P 500 companies in the green on Wednesday. Gilead

Wellcome Trust

When will we have a coronavirus vaccine? Human trials to begin in April | The Telegraph | 3/3/2020

Wellcome Trust a further £10 million. Earlier this week executives from pharmaceutical companies Gilead, Johnson & Johnson, GlaxoSmithKline, Sanofi and Pfizer met with Donald Trump to assure the US president they were making rapid progress in vaccines and antivirals. To date, some 35 companies and institutions are working on the problem worldwide and the US is the furthest ahead with development. Dr Antony Fauci, the head of the US National Institute …

Zacks Investment Research

Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher | Yahoo News | 2/27/2020

Gilead Sciences, Inc. GILD was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands … See their latest picks free Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD …

SunTrust Banks

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American International Group Inc. - Ticker Report | 2/10/2020

American International Group Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and … been the topic of a number of recent research reports. SunTrust Banks initiated coverage on shares of Gilead Sciences in a research report on Tuesday, November 12th. They issued a “hold” rating and a $70.00 …

Zacks Equity Research

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences | 2/7/2020

Read More Hide Full Article For Immediate Release Chicago, IL – February 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Exxon Mobil ( XOM - Free Report ) , Chevron ( CVX - Free Report ) , International Business Machines ( IBM - Free Report ) , Gilead Sciences ( GILD - Free Report …

SunTrust Bank

Gilead Sciences (NASDAQ:GILD) Updates FY 2020 After-Hours Earnings Guidance | 2/5/2020

Gilead Sciences (NASDAQ:GILD) updated its FY 2020 After-Hours earnings guidance on Tuesday. The company provided earnings per share guidance of 6.05-6.45 for the period, compared to the Thomson Reuters consensus earnings per share … a hold rating in a report on Friday, October 25th. SunTrust Banks initiated coverage on Gilead Sciences in a report on Tuesday, November 12th. They issued a hold rating and a $70.00 target price on …

Vida Ventures

Health tech funding snapshot—Virta Health lands $93M; Andreessen Horowitz invests in Komodo Health | FierceHealthcare | 2/4/2020

Gilead Sciences to pursue its goal of treating or curing autoimmune diseases using patients’ own cells. Kyverna has raised $25 million in series B funding from Gilead, Vida Ventures and Westlake Village BioPartners. Data analytics: Clinical analytics solutions company Covera Health landed $23 million in series B financing, led by Insight Partners, with participation from existing investors, including Prism Ventures. Consumer experience platform: Zipari , an insurance software startup, nabbed $22.5 …

Flagship Pioneering

Sandra Horning, M.D. To Join Moderna’s Board of Directors | Business Wire | 2/3/2020

… experience in bringing transformative medicines to patients,” said Noubar Afeyan, Ph.D., Co-Founder and Chairman of Moderna, and CEO of Flagship Pioneering. “Sandra is a true visionary with a highly distinguished career and we believe … lower prices, and serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). Previously she served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche from 2014 to 2019 …

JP Morgan

Coronavirus, earnings, jobs: What to know in the week ahead | Yahoo News | 2/3/2020

… customers and workers exposed to the deadly virus. Airlines, including American Airlines and Delta, have suspended flights to China, and JP Morgan Chase, Ford and Kraft Heinz have each rolled out employee travel bans to … JKHY ), Ford ( F ), Mueller Water Products ( MWA ), Cerner Corporation ( CERN ), Gilead Sciences ( GILD ), Disney ( DIS ), Snap ( SNAP ), Match Group ( MTCH ) after market close Wednesday: General Motors ( GM ), Boston Scientific Corporation ( BSX ), Humana ( HUM ), Merck & Co …

Silicon Valley Bank

World Antibody Drug Conjugates Market, 2019-2030 - Analysis & Outlook by Type of Payload, Type of Linker, Target Indications, Target Antigens, and Technology Providers | Benzinga | 1/23/2020

… de solidarit FTQ Forbius Formex Formosa Laboratories Fortis Therapeutics Fosun Pharma Foundation Medicine F-Prime Capital GamaMabs Pharma Genentech Genmab Gilead Sciences Global Bio Glycotope Glykos Goodwin Biotechnology GP-Pharm GSK GT Biopharma Halozyme Therapeutics … Shanghai Miracogen Shanghai Pharma Shenogen Pharma Shire Siamab Therapeutics Siegfried Silicon Valley Bank Sinopharm Capital Skyline Ventures Sorrento Therapeutics SOTIO Spectrum Pharmaceuticals Spirogen SpringWorks Therapeutics SR One STA Pharmaceutical Starling Ventures Stason Pharmaceuticals Stemcentrx Sun …

Bill & Melinda Gates Foundation

A coalition backed by Bill Gates is funding biotechs that are scrambling to develop vaccines for the deadly Wuhan coronavirus | Business Insider | 1/23/2020

… days. The effort is funded by the Coalition for Epidemic Preparedness Innovations , a group started by Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum. CEPI is also … long it might take to make a vaccine. Biotech giant Gilead Sciences is also considering repurposing an experimental drug previously tested against Ebola as a treatment against this new strain, according to Bloomberg Law . The …

Wedbush Securities

Buckley Wealth Management LLC Sells 6,952 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) | 1/17/2020

Buckley Wealth Management LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The … after buying an additional 244 shares in the last quarter. Wedbush Securities Inc. grew its position in Gilead Sciences by 17.7% during the fourth quarter. Wedbush Securities Inc. now owns 23,959 shares of the biopharmaceutical …

Piper Jaffray

Despite Intense Public, Congressional Scrutiny, Pharma Still Hikes Prices For Hundreds Of Drugs In 2020 | Kaiser Health News | 1/3/2020

… Pharma Still Hikes Prices For Hundreds Of Drugs In 2020 “The more things change, the more they stay the same,” Piper Jaffray analyst Christopher Raymond wrote in a note to investors, pointing out that the … Drug Makers Boost Prices For The New Year For instance, Gilead Sciences (GILD) increased prices for several HIV pills by 4.8%, Biogen (BIIB) boosted its Tecfidera multiple sclerosis treatment by 6%, Eli Lilly (LLY) raised …

RBC Capital Markets

6 High-Yield Dividend Stocks Wall Street Likes For Investors In 2020 | Forbes | 12/28/2019

… the market is more volatile than forecasters think. With that in mind, here are six high-yielding dividend stocks from RBC Capital Markets’ “Top 30 Global Ideas for 2020” report that investors can consider in … investments undertaken by both SunTrust and BB&T,” Cassidy writes. Gilead Sciences, Inc. (Dividend Yield: 3.8%) The biotech giant’s attempts to extend the patent on anti-HIV drug Descovy have drawn the ire of politicians …

Biogen Idec

Visiongain Report Offers Transformative Insights on the $11bn Biological Drug API Manufacturing Market | PR Newswire | 12/3/2019

PRNewswire/ – The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry . How this 211-page Visiongain report delivers: • Biological Drug API Manufacturing Services market forecast to 2029 • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems …

Third Rock Ventures

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma [Research Articles] | 12/2/2019

… from Novartis, GSK, Toray Industries, Celgene, Hengrui Therapeutics, OncoMed, Tesaro, AADi, Merck, Inhibrx Inc., AMAL Therapeutics, Syndax, Millennium, Johnson & Johnson, Gilead Sciences, Plexxikon, Onyx, Blueprint Medicines, XuanZhu, and Incyte, has ownership interest (including patents) in … Executive Vice President at Blueprint Medicines, is a partner at Third Rock Ventures, is a director at Hookipa, is a scientific advisory board member for Mersana, and has ownership interest (including patents) in Blueprint Medicines …

SVB Leerink

The return of the megamerger | 12/2/2019

… of deal: Cholesterol-lowering drug in late-stage studies Source: Companies According to an analysis done by the investment firm SVB Leerink, global pharmaceutical merger and acquisition activity is on track to hit a 10 … a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis pays Takeda Pharmaceutical $3.4 billion to acquire the dry-eye …

Maxim Group

Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of “Buy” by Analysts | 12/2/2019

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been assigned a consensus rating of “Buy” from the twenty-eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock … hold” rating in a research report on Friday, October 25th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Raymond James set a …

Sofinnova Ventures

Global Viral Vectors, Non-Viral Vectors & Gene Therapy Manufacturing Market, 2019-2030 - Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA & Other Vectors | PR Newswire | 11/28/2019

Global Viral Vectors, Non-Viral Vectors & Gene Therapy Manufacturing Market, 2019-2030 - Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA & Other Vectors News provided by Research and Markets Nov 28, 2019, 08:45 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)” report has been added to ResearchAndMarkets.com’s offering. This …

OrbiMed Advisors

Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors | PR Newswire | 11/26/2019

… University of South Florida , and his M.D. from the University of Virginia . Mona Ashiya, Ph.D, is currently a Partner at OrbiMed Advisors, LLC, a healthcare focused investment firm. She has been at OrbiMed since 2010 … common stock and a warrant to purchase common stock to Gilead Sciences, Inc. (Gilead) in consideration for amending the royalty rates and milestones in an Asset Purchase Agreement with Gilead for momelotinib, subject to certain …

Longitude Capital

Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors | PR Newswire | 11/26/2019

… Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University . Josh Richardson , M.D., has served as Managing Director of Longitude Capital since February 2016 where he focuses on investments in biotechnology companies. From September … common stock and a warrant to purchase common stock to Gilead Sciences, Inc. (Gilead) in consideration for amending the royalty rates and milestones in an Asset Purchase Agreement with Gilead for momelotinib, subject to certain …

Jefferies Financial Group

Gilead Sciences (NASDAQ:GILD) Given a $86.00 Price Target by Guggenheim Analysts | 11/20/2019

Gilead Sciences (NASDAQ:GILD) Given a $86.00 Price Target by Guggenheim Analysts Posted by Sean Solarzano on Nov 20th, 2019 Gilead Sciences (NASDAQ:GILD) has been assigned a $86.00 target price by research analysts at … a “buy” rating in a report on Tuesday, October 15th. Jefferies Financial Group set a $95.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th …

Comerica Bank

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Texas Permanent School Fund | 11/17/2019

Texas Permanent School Fund decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC … after purchasing an additional 20,425 shares in the last quarter. Comerica Bank raised its position in shares of Gilead Sciences by 4.7% in the 3rd quarter. Comerica Bank now owns 365,858 shares of the biopharmaceutical …

Kaiser Permanente

WHO officials enroll first patients from Norway and Spain in ‘historic’ coronavirus drug trial | CNBC | 3/27/2020

… and more trials are needed. Scientists have also been looking at HIV drugs as possible treatments. Remdesivir is produced by Gilead Sciences. Some health authorities in the U.S. and China have been using the drug … coat of the new coronavirus, according to researchers at the Kaiser Permanente Washington Health Research Institute …

Northwell Health

Coronavirus: Cramer says investors should not bet against science | CNBC | 3/27/2020

Northwell Health CEO Michael Dowling , who told CNBC on Thursday that trials underway at his hospital system are showing signs of progress. Northwell Health, the largest health-care provider in New York state, is working with Regeneron and Gilead Sciences to test the efficacy of existing drugs. The trials have not produced “definitive results yet,” Dowling cautioned on “ Squawk on the Street .” “But I am pretty certain that within the …

Harvard Medical School

Covid-19: Gilead withdraws orphan drug designation from potential treatment after criticism | BMJ | 3/26/2020

… from a potential covid-19 treatment, after criticism that treating covid-19 as a rare disease was “disingenuous.” Pharmaceutical company Gilead requested that the FDA withdraw the designation—which was set to give the company … the programme on regulation, therapeutics, and law, Ameet Sarpatwari, from Harvard Medical School, said, “The Orphan Drug Act was intended to spur the development of drugs for which there was no reasonable expectation of generating …

Massachusetts General Hospital

Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More - March 25, 2020 - Zacks.com | 3/25/2020

… of COVID-19 and updates from these companies will drive their share prices. Recap of the Week’s Most Important Stories : Gilead’s HCV Drug Epclusa Gets FDA Nod for Expanded Age Group : Gilead Sciences ( GILD - Free … by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). Both companies will jointly explore and develop this SAV technology as a means to help patients at risk of being infected …

Baylor College of Medicine

Researchers turn to shelved SARS vaccines for COVID-19 | Fortune | 2/19/2020

… to at least a dozen. Other drug makers in the battle include Johnson & Johnson (which is also working with BARDA ), Gilead , GlaxoSmithKline, Moderna, Inovio, and Novavax, as well as various public medical institutes. Some of … vaccine was shelved, as was another SARS vaccine from the Baylor College of Medicine and its partners. What makes that kind of freeze frustrating during new outbreaks is that such treatments, if advanced to clinical …

Memorial Sloan Kettering

CAR-T patent damages at $1.5B? BMS urges court to hike $752M award against Gilead - FiercePharma (0 visits) | 1/23/2020

CAR-T patent damages at $1.5B? BMS urges court to hike $752M award against Gilead by Jan 23, 2020 11:15am Bristol-Myers owns Juno Therapeutics after its buyout last year of Celgene. (BMS) In a … Therapeutics had licensed from researchers at Sloan Kettering and the Memorial Sloan Kettering Cancer Center. The jury ordered Kite, now part of Gilead, to pay $752 million in damages. That number was calculated based on …

Dignity Health

Lloyd Dean will become the sole CEO of CommonSpirit Health | FierceHealthcare | 1/23/2020

… have served 17 years as CEO and 22 years as an executive with Catholic Health Initiatives (CHI) which merged with Dignity Health last year to form CommonSpirit. Since the merger in February, Lofton and Dean … system in U.S. history. Lofton serves on the boards of Gilead Sciences, Inc., the Rite Aid Corp., and the GSU Foundation and previously served on the boards of the Catholic Health Association and the GSU …

Memorial Sloan Kettering Cancer Center

Kite Pharma ordered to pay Juno Therapeutics $752M in CAR-T drug infringement case | Becker’s Hospital Review | 12/16/2019

A federal jury Dec. 13 ordered Gilead Sciences subsidiary Kite Pharma to pay $752 million to Bristol-Myers Squibb subsidiary Juno Therapeutics for allegedly violating a patent when developing its CAR-T drug, Yescarta, according to MedCity News . In 2017, Kite received approval for Yescarta, designed to treat lymphoma. Juno then sued Kite, alleging it used research patented by Memorial Sloan Kettering Cancer Center and licensed by Juno to develop …

MD Anderson Cancer Center

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… government plans to distribute the drugs for pre-exposure prophylaxis, or PrEP, that were promised in May by the drugmaker Gilead Sciences. (McNeil, 12/3) The Associated Press: Health Program Offers Free HIV Prevention Drug To … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

University of Texas MD Anderson Cancer Center

The return of the megamerger | 12/2/2019

… a deal worth $13.4 billion. Amgen pays $2.7 billion for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact. Novartis … He also has leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took responsibility …

HCA

Nov 15, 2019 - Bellevue Group AG Buys Glaukos Corp, Arvinas Inc, Becton, Dickinson and Co, Sells Celgene Corp, Gilead Sciences Inc, Teladoc Health Inc - GuruFocus.com | 11/15/2019

Gilead Sciences Inc, Teladoc Health Inc, Avedro Inc, Quidel Corp during Bellevue Group AG. As of 2019Q3, Bellevue Group AG owns 209 stocks with a total value of $5.4 billion. These are the details of the buys and sells. New Purchases: ARVN , PACB , MYL , TXG , SDC , HCAT , BIO , XLRN , ZGNX , TEVA , PTLA , JNJ , CRL , MNTA , LVGO , LIN , PAYX , CLX , STML , XLNX , ADMS , Added Positions: IONS , GKOS , AGIO , BDX , ABT , INSM …

Geisinger

First Edition: November 11, 2019 | Kaiser Health News | 11/11/2019

… Drugs? The Taxpayers, U.S. Says After years of prodding by patient advocates, federal officials on Wednesday sued the drug maker Gilead Sciences, charging that it had infringed government patents on the idea of preventing H.I.V … Traced To Contaminated Equipment, Hospital Says The infants at the Geisinger Medical Center in Danville, Pa., neonatal intensive care unit were tiny, with some born 27 weeks premature. In July, some started to get ill …

Cleveland Clinic

‘It Hurts. Don’t Do It’: What We Heard This Week | 11/8/2019

… the more pleasant surprises.” – Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, on a federal lawsuit against Gilead Sciences over patents related to HIV prevention medications . “Social media has been extremely weaponized … basic knowledge, can use that.” – Ali Aminian, MD, of the Cleveland Clinic, on a web-based calculator that predicts individualized outcomes after bariatric surgery. 2019-11-08T17:30:00-0500 …

Seattle Cancer Care Alliance, Seattle WA

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy | Blood Advances | American Society of Hematology | 10/22/2019

… Acknowledgments The authors thank the clinical providers, nurses, and research staff in the transplant and immunotherapy programs at Fred Hutch, Seattle Cancer Care Alliance, and the University of Washington. The Fred Hutchinson Cancer Research Center … and has received research funding from Mustang Biopharma, Celgene, Pharmacyclics, Gilead Sciences, Genentech, AbbVie, TG Therapeutics, BeiGene, Acerta Pharma, Merck, and Sunesis. R.D.C. has received research funding from Amgen, Incyte, Kite/Gilead, Merck, Pfizer, and …

Cleveland Clinic, Cleveland OH

Companies Seek an Innovative Solution to the Growing Cancer Rates | Benzinga | 9/30/2019

… of 9.6% during the forecast period. INmune Bio, Inc. (NASDAQ: INMB ), Celgene Corporation (NASDAQ: CELG ), Merck & Co., Inc. (NYSE: MRK ), Gilead Sciences, Inc. (NASDAQ: GILD ), Pfizer Inc. (NYSE: PFE ) Immunotherapy can be used to treat … DO, Vice Chairman of rheumatic and immunologic disease, at the Cleveland Clinic at the Seventh Annual Basic and Clinical Immunology for the Busy Clinician symposium. “Immunotherapy is now a pillar of cancer treatment — it is …

HCA Healthcare

Camber Capital Management LLC Buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, Sells … | 8/20/2019

Boston, MA, based Investment company Camber Capital Management LLC ( Current Portfolio ) buys HCA Healthcare Inc, Gilead Sciences Inc, Mylan NV, United Therapeutics Corp, DaVita Inc, sells Global Blood Therapeutics Inc, Biogen Inc, NuVasive Inc, Clovis Oncology Inc, Alexion Pharmaceuticals Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Camber Capital Management LLC. As of 2019Q2, Camber Capital Management LLC owns 30 stocks …

Renown Health

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH) | Health IT Outcomes | 7/11/2019

Subscribe To Our Newsletter News July 11, 2019 Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH) FOSTER CITY, CALIF. & RENO, NEV.–(BUSINESS WIRE)– Gilead Sciences … the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and …

Moffitt Cancer Center

Award Celebrates 40 of Oncology’s Rising Stars and Emerging Leaders Under Age 40 | PRWeb | 6/3/2019

… MD, Stanford University Justin Birckbichler, Founder, ABSOT (A Ballsy Sense of Tumor) Kevin Hays, Savarino Companies, LLC Kip Cross, MBA, Gilead Sciences/Kite Kristin Marie Ferguson, DNP, RN, OCN, Medstar Georgetown University Hospital Kyle Smith … A. Fajuri, JD, Cancer Legal Resource Center Stephen Rosenberg, MD, Moffitt Cancer Center Tiffany Kendig, PT, DPT, MPH, CLT, Kessler Rehabilitation Xavier Keutgen, MD, FACS, University of Chicago Medical Center About The Lynx Group The …

Fred Hutchinson Cancer Research Center, Seattle WA

Seattle Cancer Care Alliance Selected as Authorized Treatment Center for Yescarta™ - A Novel, New Immunotherapy Treatment | PR Newswire | 12/8/2017

… currently offer axicabtagene ciloleucel (axi-cel, also known by the brand name Yescarta ™), a new immunotherapy, developed by Kite (a Gilead company), to help treat adults living with relapsed or refractory large B-cell lymphoma … Cancer Care Alliance and medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, SCCA’s research partner. “The agency’s approval of this new therapy will likely help save thousands of lives over the next …

Aetna

The Zacks Analyst Blog Highlights: Toyota, CVS, 3M, Gilead and Goldman | 12/11/2019

… recently featured in the blog include: Toyota Motor ( TM - Free Report ) , CVS Health ( CVS - Free Report ) , 3M ( MMM - Free Report ) , Gilead Sciences ( GILD - Free Report ) and Goldman Sachs ( GS - Free Report ) . Here are highlights from … its expectations. The Health Care Benefits segment, launched after the Aetna acquisition, is showing strong momentum. The company posted better-than-expected third-quarter results on the back of robust progresses. However, persistent reimbursement pressure …

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… tisagenlecleucel), first approved in August 2017, costs $475,000 or $373,000 depending on the type of cancer it’s used for; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel), also a CAR-T … OptumRx. CVS Health, which owns CVS Caremark PBM, purchased insurer Aetna late last year in a $69 billion deal, while insurer Cigna finalized its $54 million purchase of Express Scripts Holding Co. in late December …

Cigna

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… tisagenlecleucel), first approved in August 2017, costs $475,000 or $373,000 depending on the type of cancer it’s used for; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel), also a CAR-T … late last year in a $69 billion deal, while insurer Cigna finalized its $54 million purchase of Express Scripts Holding Co. in late December 2018. Finally, Anthem Inc. is launching its own in-house PBM …

Obscure Model Puts a Price on Good Health – and Drives Down Drug Costs | MSN | 11/4/2019

… Medicare program in the 2010 Affordable Care Act. “This is a cultural issue,” says Steve Miller, chief clinical officer at Cigna Corp., an insurer. “This is America not wanting to put a value on the … radiation therapy for cancer. Its focus shifted in 2013, when Gilead Sciences Inc.’s hepatitis C drug Solvadi-—the first $1,000-a-pill drug—hit the market. ICER found that Solvadi was cost-effective but …

Humana

ICER Will Take Different Approach to Assess Short-Term, High-Impact Products | 12/2/2019

… tisagenlecleucel), first approved in August 2017, costs $475,000 or $373,000 depending on the type of cancer it’s used for; and Gilead Sciences, Inc. unit Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel), also a CAR-T … completed its acquisition of DaVita Medical Group for $4.9 billion. Humana Inc. last year bought Family Physicians Group, a large Orlando, Fla.-based physician group that provides care through at-risk payment arrangements. In addition …

Nov 19, 2019 - Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data Processing Inc, Sells Eli Lilly and Co, NetApp Inc, CenterPoint Energy Inc - GuruFocus.com | 11/19/2019

Columbia, SC, based Investment company Ccm Investment Advisers Llc ( Current Portfolio ) buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data Processing Inc, sells Eli Lilly and Co, NetApp Inc, CenterPoint Energy Inc, Humana Inc, ScanSource Inc during the 3-months ended 2019Q3, according to the most recent filings of the investment company, Ccm Investment Advisers Llc. As of 2019Q3, Ccm Investment Advisers Llc owns 65 stocks with a total …

WellCare Health

The 2019 CPA-Zicklin Index of Corporate Political Disclosure and Accountability | 11/12/2019

… Corp.; Dominion Energy Inc.; Edison International; Entergy Corp.; Estee Lauder Companies Inc.; Exelon Corp.; General Electric Co.; General Mills Inc.; Gilead Sciences Inc.; Hartford Financial Services Group Inc.; Honeywell International Inc.; Host Hotels & Resorts Inc … Group Inc.; Unum Group; Visa Inc.; Walgreens Boots Alliance Inc.; WellCare Health Plans, Inc.; and The Williams Companies Inc. Basement-Dwellers And Backsliders The 2019 Index data show 59 companies from the S&P 500 …

Partner Fund Management, L.P. Buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences … | 8/20/2019

San Francisco, CA, based Investment company Partner Fund Management, L.P. ( Current Portfolio ) buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences Inc, Sarepta Therapeutics Inc, Alibaba Group Holding, sells UnitedHealth Group Inc, Blueprint Medicines Corp, Arena … shares, 3.37% of the total portfolio. Shares added by 22.52% WellCare Health Plans Inc ( WCG ) - 480,244 shares, 3.37% of the total portfolio. Shares added by 44.29% New Purchase: Biomarin Pharmaceutical Inc ( BMRN ) Partner Fund Management …

Molina Healthcare

WRL for Nov 2 | 11/2/2019

… 97.13 2.50 ▼ 40 26.20% Fox Corp FOX 31.86 33.75 -4.10 ▲ 12 9.69% Fox Corp FOXA 32.39 34.18 -3.68 ▲ 31 12.25% Gilead Sciences Inc GILD 64.66 66.15 -0.82 ▲ 15 0.98% Alphabet Inc GOOG 1273.74 1171.90 3.34 … 37 26.47% MAXIMUS Inc MMS 75.80 73.72 0.46 ▼ 12 0.50% Molina Healthcare MOH 118.83 127.73 -2.98 ▲ 13 6.84% Medical Properties Trust MPW 20.82 18.82 5.84 ▲ 17 14.02% pP Monolithic Power Systems MPWR 155.58 141.82 0.46 …

WRL for Oct 5 | 10/5/2019

… 95.57 5.02 ▼ 36 24.84% Fox Corp FOX 30.49 34.81 -4.89 ▼ 8 13.59% Fox Corp FOXA 30.57 35.08 -4.88 ▼ 27 17.18% Gilead Sciences Inc GILD 62.56 66.55 -1.01 ▼ 11 4.20% Alphabet Inc GOOG 1209.00 1145.56 3.02 … 33 25.27% MAXIMUS Inc MMS 75.91 73.61 3.12 ▼ 8 0.65% Molina Healthcare MOH 112.77 130.30 -4.39 ▼ 9 11.59% Medical Properties Trust MPW 19.47 18.14 3.20 ▲ 13 6.63% Monolithic Power Systems MPWR 152.93 142.38 3.93 ▼ 12 …

Alex Azar

FDA to fast-track COVID-19 therapies | Modern Healthcare | 4/2/2020

Alex Azar said in a press release . There are 10 therapy in active trials and another 15 in planning stages, according to the agency. Among them are Gilead’s remdesivir and interleukin-6 which can help reduce lung inflammation and function in COVID-19 patients. Several hospitals across the country are also in trials to see if plasma from the blood of patients who have recovered from the virus could shorten …

Nick Taylor

EuroBiotech Report—Lilly-Sitryx, Genfit and COVID-19, Gilead tests remdesivir in U.K. and more | FierceBiotech | 4/2/2020

Gilead began to test its antiviral remdesivir in the U.K. The NIHR Clinical Research Network, a major U.K. biomedical body, shut down in response to COVID-19 And more. — Nick Taylor 1. Lilly pays Sitryx $50M upfront for preclinical autoimmune assets Eli Lilly has paid Sitryx $50 million (€46 million) upfront for global rights to up to four autoimmune drugs. The deal sees Lilly commit to up to $820 million …

Warren Buffett

Can Buffett-Style Investing Succeed Today? Stocks & ETFs to Consider - April 2, 2020 - Zacks.com | 4/2/2020

… and the VanEck Vectors Morningstar Wide Moat ETF ( MOAT - Free Report ) . The term “economic moat” was popularized by legendary investor Warren Buffett who said that he seeks “economic castles protected by unbreachable moats.” In simple … NOW - Free Report ) –provides enterprise cloud computing solutions. Biotech giant Gilead ( GILD - Free Report ) , which is conducting multiple clinical trials of coronavirus drug remdesivir, is another top holding. There are some “hidden gems” too. For …

Jim Cramer

10 Best Stocks in Nasdaq for March; Buy or Sell? - TheStreet | 4/1/2020

The best stocks in the Nasdaq for March include Amazon, Gilead Sciences and Netflix. See the best stocks in the Nasdaq for March 2020. Author: Danny Peterson Updated: Apr 1, 2020 9:37 AM EDT Original … news on any given day, the rating may differ from Jim Cramer's view or that of this articles' author. Amazon is a key holding in Jim Cramer's Action Alerts PLUS …

Donald Trump

Report: Trump sets sights on another unproven Covid-19 drug, this time from Fujifilm - MedCity News | 4/1/2020

President Donald Trump and his administration want regulators to give emergency use authorization to a drug to treat Covid-19 despite its having limited supporting data and potentially serious side effects. This time, it’s not … Other drugs currently in clinical development for Covid-19 include Gilead Sciences’ remdesivir, Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab). Gilead is expected to have data for remdesivir this month. Photo: FDA (free of all copyright …

Anthony Fauci

‘Panic Prescribing’ Untested Coronavirus Treatments: A Danger To Patients Today and Tomorrow | Health Affairs | 3/31/2020

… of which have been approved by the Food and Drug Administration for COVID-19: remdesivir , an experimental product developed by Gilead as a possible treatment for Ebola Virus Disease that currently is not approved for … know how to treat this disease. Both FDA and Dr. Anthony Fauci have sought to clarify the record, emphasizing the lack of data and critical need to study these and other drugs to determine what …

Daniel O’Day

Gilead transitioning to ‘expanded access’ program for experimental COVID-19 treatment | Becker’s Hospital Review | 3/30/2020

Gilead transitioning to ‘expanded access’ program for experimental COVID-19 treatment Maia Anderson - Print Email Gilead Sciences is transitioning to an “expanded access” program for its experimental COVID-19 treatment, remdesivir, because its current program can’t support the “overwhelming” number of applications, Gilead CEO Daniel O’Day, wrote in an open letter published March 28. Gilead has been testing remdesivir as a treatment for COVID-19 and Mr. O’Day said the …

Bernie Sanders

FiercePharmaPolitics—Congress’ stimulus likely pushes back drug pricing action | FiercePharma | 3/30/2020

Gilead asks FDA to rescind remdesivir orphan drug tag after public backlash Lastly, Gilead Sciences found itself in a dust-up over potential pricing on remdesivir to treat COVID-19. After the company scored an FDA orphan drug designation—and market exclusivity—critics including Sen. Bernie Sanders hit back. Gilead has asked the FDA to rescind the designation, and the company’s CEO Daniel O’Day wrote this weekend that the company …

Tedros Adhanom Ghebreyesus

Malaria drug Trump touted as coronavirus cure given FDA okay | Fortune | 3/30/2020

… Let’s see how it works,” Trump said in his daily briefing Sunday. “It may, it may not.” WHO Director-General Tedros Adhanom Ghebreyesus has cautioned against the use of unproven treatments against coronavirus. “The history … desperately ill and contagious patients. A variety of treatments, including Gilead Sciences Inc.’s remdesivir, are currently in randomized, controlled clinical trials . Scientists are also investigating the utility of a vaccine against tuberculosis that’s been …

Vas Narasimhan

Novartis CEO says Malaria drug is biggest hope against coronavirus - SonntagsZeitung | Yahoo News | 3/29/2020

ZURICH (Reuters) - Novartis Chief Executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against the coronavirus, Swiss newspaper SonntagsZeitung reported on Sunday. Novartis has pledged … have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing its experimental drug remdesivir against coronavirus. “Pre-clinical studies in animals as well as the first data from clinical studies show …

Tim Cook

Wall Street: bullish momentum halted, negative short US rates | Yahoo News | 3/26/2020

Gilead and Vertex -5.8%, Amgen -4.6%, Regeneron -4.4%) and drug distribution (Walgreen -8.4) sectors. %). It also suffered from the decline of Intel -2.2% and Cisco -2.4%, AMD -3.4%, and Facebook -3%, Netflix -4.2%, Electronic Arts -5, 9%. Note that Tim Cook, the CEO of Apple announces offering 10 million masks to the American medical community, which seems to demonstrate that there are still suppliers who can deliver in large numbers …

Andrew Harnik

FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments | NPR | 3/25/2020

Enlarge this image Gilead Sciences CEO Daniel O’Day (center) took part in a meeting of the White House Coronavirus Task Force on March 2. Andrew Harnik/AP Andrew Harnik/AP Gilead Sciences CEO Daniel O’Day (center) took part in a meeting of the White House Coronavirus Task Force on March 2. Andrew Harnik/AP The Food and Drug Administration gave an experimental medicine called remdesivir to treat COVID-19 what’s …

Melinda Gates

Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis | PR Newswire | 3/23/2020

… in the markets this week include CNS Pharmaceuticals, Inc. (NASDAQ: CNSP ), Sorrento Therapeutics, Inc. (NASDAQ: SRNE ), Moderna, Inc. (NASDAQ: MRNA ), Gilead Sciences, Inc. (NASDAQ: GILD ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ). Health officials from WHO have … has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA ® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA …

Elon Musk

Trump Touts Malaria Drug As Possible Virus Treatment But FDA Strikes More Cautious Tone | Kaiser Health News | 3/20/2020

… Food and Drug Administration Commissioner Dr. Stephen Hahn cited the malaria drug chloroquine, along with remdesivir, an experimental antiviral from Gilead Sciences, and possibly using plasma from survivors of COVID-19, the disease the new … a decades-old malaria drug work to treat COVID-19? Elon Musk seems to think so, recently tweeting that it “might be worth considering chloroquine” for COVID-19. Although data are spare, studies so far …

Mike Pence

Potential coronavirus treatment touted by Trump already in shortage, say pharmacists | MSN | 3/19/2020

… already in shortage, say pharmacists Reuters 13 hrs ago By Michael Erman © Reuters U.S. President Donald Trump and Vice President Mike Pence visit the Federal Emergency Management Agency headquarters, in Washington, U.S. March 19, 2020 … vaccines. He said the government was looking at hydroxychloroquine and Gilead Sciences Inc’s experimental antiviral drug remdesivir, which is undergoing clinical trials for the respiratory illness. News to stay informed. Advice to stay safe. Click …

Geoffrey Porges

Look for novel coronavirus treatments first, experts say, and vaccines are farther off than you think | FiercePharma | 3/13/2020

What’s the outlook for really fending off the novel coronavirus? Small molecule drugs and other therapeutics will obviously beat vaccines to market, and Gilead’s remdesivir, if effective, could scale up fast, experts said. Vaccines are likely farther off than quoted timelines suggest. It’s “overly optimistic” to expect them in 12 to 18 months, two opinion leaders told SVB Leerink analyst Geoffrey Porges. They’re “relatively optimistic” about Gilead’s remdesivir “being effective …

Bill Gates

Morningstar’s View: The Impact of Coronavirus on the Economy | Morningstar | 3/10/2020

… and the working-age population. We see reason for optimism surrounding vaccines and treatments. We should see initial data from Gilead’s ( GILD ) remdesivir by April; this drug could be a strong defense for patients with … Transmissibility is also difficult to estimate during a pandemic, but Bill Gates noted that this virus has already infected 10 times the number of total SARS cases, and in only one fourth of the time …

Joe Biden

Dow slides more than 900 points as coronavirus continues to hit fear-filled markets | Markets Insider | Business Insider | 3/5/2020

… trading session on Wednesday that drove a 4% gain for all three major US indices. Health care firms soared on Joe Biden’s unexpectedly strong Super Tuesday performance, calming Wall Street’s worries that a progressive candidate … and Business Insider: One Wall Street firm says approval for Gilead’s experimental coronavirus treatment is a coin-flip bet at best — but still thinks you should buy the stock right now These 3 hedge fund …

Bob Iger

Barron’s Picks And Pans: COVID-19 Stocks, Intel, Tesla And More | Yahoo News | 3/1/2020

… according to “ How the Coronavirus Will Challenge the Health-Care Industry “ by Josh Nathan-Kazis. See what that means for Gilead Sciences, Inc. (NASDAQ: GILD ) and others. In Daren Fonda’s “Venture Capital Attracts the Corporate … tackle the fallout for oil prices Whether Disney’s sequel to Bob Iger looks like a hit At the time of this writing, the author had no position in the mentioned equities. Keep up with all …

Jeff Bezos

Donald Trump Jr. says Dems hope coronavirus “comes here and kills millions” and ends his dad’s “streak of winning” | Business Insider | 2/28/2020

Jeff Bezos reportedly just spent $165 million on a Beverly Hills estate — here are all the ways the world’s richest man makes and spends his money See Also: The coronavirus has pandemic ‘potential’ as it spreads in South Korea, Italy, and Iran, according to WHO The $95 billion biotech Gilead just announced plans to test a promising potential coronavirus treatment in 1,000 people Microsoft and Chevron are among 13 of …

Laura Wood

Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020 - ResearchAndMarkets.com | Business Wire | 2/27/2020

… Asana BioSciences LLC Beijing Hanmi Pharmaceutical Co Ltd Bristol-Myers Squibb Co Clevexel Pharma SAS Fujifilm Holdings Corp Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Hutchison MediPharma Ltd Japan Tobacco Inc Levolta Pharmaceuticals Inc Millennium … drug pipelines report visit https://www.researchandmarkets.com/r/epy5e9 Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call …

Hillary Clinton

Buffett still undecided in presidential race - The Boston Globe | 2/25/2020

… interview with CNBC. “Normally, I vote for Democrats. We will see what happens.” Buffett, who runs Berkshire Hathaway Inc., endorsed Hillary Clinton for the 2016 election against now-President Trump, and attended fund-raisers for … the deal weren’t disclosed in Monday’s announcement. — BLOOMBERG NEWS PHARMACEUTICALS Gilead stock rises after WHO comment Gilead Sciences Inc. shares gained Monday after a senior World Health Organization official said the company’s experimental drug may …

Amy Klobuchar

Southeastern Conference hires a lobbying firm in college athletics fight - POLITICO | 2/13/2020

… Partners has signed seven new lobbying clients, the most notable of which are probably the pharmaceutical companies Eli Lilly and Gilead Sciences . Former Rep. Ed Royce (R-Calif.), who left Congress last year, Marc Lampkin … Health Care Future ,” which opposes proposals advanced by Joe Biden , Amy Klobuchar and other more moderate Democrats for a public option as well as Medicare for All. — The union “will direct its network of members …

Elizabeth Warren

Sic transit gloria mundi. Latin for what’s happening today. | 2/10/2020

… stock market, big-time. Today it’s up. I can’t play this short-term game. Ed can. He’s good at it. Gilead has an antiviral drug which may cure coronavirus. They’re testing the drug in Wuhan … on Saudi oil. We are now the world’s largest producer. Elizabeth Warren, however, has pledged to ban fracking on her first day in office! Sic transit gloria mundi. A great way to end today’s blog …

Pete Buttigieg

Sanders Embarrasses Trump During ‘CNN Sunday’ Appearance | 2/9/2020

… thing). Leading candidates in the Democratic presidential primary field include Vermont’s Senator Bernie Sanders and South Bend, Indiana’s former mayor, Pete Buttigieg. This weekend during an appearance on CNN’s State of the Union , Sanders made … 2011 through 2017 as a lobbyist for the pharma company Gilead Sciences. Sanders is hoping to take this message against Trump in the general election. On average, according to RealClearPolitics, Sanders leads Trump by an …